Healthcare / Medical DevicesNasdaqGM
$3.67
+0.26 (+7.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-41.2M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$225M
P/E
N/A
•EV/EBITDA
N/A
•ROE
115.8%
↑Gross Margin
84.6%
↑Debt/Equity
-1.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-41.9%
FCF / Net income
0.48x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $45.2M · net income $-39.2M · FCF $-18.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $45.2M | $45.2M | $29.4M | $18.5M | $12.4M | — | — |
| Net Income | $-39.2M | $-39.2M | $-30.0M | $-59.4M | $-47.2M | $4.8M | — |
| EBITDA | $-33.0M | $-33.0M | $-26.2M | $-58.7M | $-46.8M | — | — |
| EPS | — | — | -1.31 | -6.73 | -161.55 | — | — |
| Gross Margin | 84.6% | 84.6% | 86.1% | 85.9% | 81.8% | — | — |
| Operating Margin | -59.7% | -59.7% | -122.9% | -294.3% | -293.9% | — | — |
| Net Margin | -86.9% | -86.9% | -102.1% | -320.7% | -380.6% | — | — |
| Balance Sheet | |||||||
| Debt/Equity | -1.02 | -1.02 | -0.91 | -0.06 | -0.01 | — | — |
| Current Ratio | 5.78 | 5.78 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-18.9M | $-18.9M | $-41.2M | $-51.2M | $-33.1M | — | — |
| Returns | |||||||
| ROE | 115.8% | 115.8% | 116.0% | 219.3% | 26.8% | -3.7% | — |
| Growth & Yield | |||||||
| Revenue Growth | 53.4% | 53.4% | 59.0% | 49.3% | — | — | — |
| EPS Growth | — | — | 80.5% | 95.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.31 → n/d
Residual
-26.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.